The Pharma Innovation Journal 2020; 9(7): 200-202

www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277- 7695
ISSN (P): 2349-8242
NAAS Rating: 5.03
TPI 2020; 9(7): 200-202

www.thepharmajournal.com
Received: 20-05-2020
Accepted: 24-06-2020

Siva Subrahmanyam Dasari
Koneru Laksmaiah Education Foundation, Department of Chemistry, Green Fields, Andhra Pradesh, India

Nareshvarma Seelam
Koneru Laksmaiah Education Foundation, Department of Chemistry, Green Fields, Andhra Pradesh, India

K Sowmya
Southern Institute Medical Sciences, Guntur, Andhra Pradesh, India

K Renuka
Southern Institute Medical Sciences, Guntur, Andhra Pradesh, India

K Praveen
Southern Institute Medical Sciences, Guntur, Andhra Pradesh, India

M Prashanthievangelin
Southern Institute Medical Sciences, Guntur, Andhra Pradesh, India

Corresponding Author:
Siva Subrahmanyam Dasari
Koneru Laksmaiah Education Foundation, Department of Chemistry, Green Fields, Andhra Pradesh, India

Nano particles: A current review

Siva Subrahmanyam Dasari, Nareshvarma Seelam, K Sowmya, K Renuka K Praveen and M Prashanthievangelin

Abstract
Nanomaterials (NMs) have gained most prominence in technological advancements to their physical, chemical and biological properties with enhanced performance over their bulk counterparts. NMs are categorized counting on their size, composition, shape, and origin. The power to predict the unique properties of NMs increases the worth of every classification. Due to increased growth of production of NMs and their industrial applications, issues concerning toxicity are inevitable. The aim of this review is to match synthetic (engineered) and present nanoparticles (NPs) and nanostructured materials (NSMs) to spot their nanoscale properties and to define the precise knowledge gaps associated with the danger assessment of NPs and NSMs within the environment. The review presents a brief summary of the history and classifications of NMs and provides a summary of the varied sources of NPs and NSMs, from natural to synthetic, and their toxicological effects towards mammalian cells and tissue. Additionally, the kinds of toxic reactions related to NPs and NSMs and therefore the regulations implemented by different countries to scale back the associated risks also are discussed.

Keywords: Particles, Nanomaterials, NMs, NSMs

Introduction
According to Environmental Protection Agency (EPA) NMs exhibits unique properties dissimilar than the equivalent compound during a larger dimension [1]. The US Food and Drug Administration (USFDA) declared NMs as materials that have a minimum of one dimension within the range of roughly 1 to 100 nm which also exhibits dimension-dependent phenomena" [2]. Similarly, the world organization for Standardization (ISO) has explained NMs as a material with any external nanoscale dimension having internal nanoscale surface structure. The synthesis of nanoparticles of various size and shape has received largest activity within the past few years as a results of their peculiar and interesting properties, and their applications superior to their bulk counterparts. The foremost successful example is microelectronics, where "smaller" has meant greater performance ever since the invention of integrated circuits which results in more components per chip, faster operation, lower cost and fewer power consumption [3].



Review Updates
R.H. Muller, O. Kayser, S.A. Wissing *et al*. discussed on the utilization of the solid lipid nanoparticles for the parenteral application of medicine, differing types of nanoparticles like solid lipid nanoparticles, nanostructured lipid carriers and lipid drug conjugate and therefore the preparation methods, stability issues and therefore the before the release of the incorporated

drugs and the biological activity of parenterally applied sln and biopharmaceutical aspects [4].

Prakash Vamanrao Diwan, Madhusudan rao, Kishan *et al.* discussed on the oral bioavailability of nitrendipine for improving its bioavailability by solid lipid nanoparticles production by hot homogenization process and characterization of the sln s produced and therefore the refore the pharmacokinetics of nitrendipine and the results improved by minimizing the primary pass metabolism [5].

Guangxi Zhai, Fengliang Cao, Jing Cui, Houli Li *et al.* discussed on the event and evaluation of penciclovir loaded solid lipid nanoparticles for topical delivery which are prepared by the double emulsion method and this concluded that sln provide an honest skin targeting effect and should be a promising carrier for topical delivery of penciclovir [6].

R.H. Muller, S.A. Runge, A.F. Thunemann, E.B. Souto *et al.* detailed the drug lipid physicochemical interations and characterization of cyclosporine loaded solid lipid nanoparticles and therefore the cyclosporine loaded sln can avoid the height plasma and keep the plasma concentrations within the therapeutic window. The emulsion the increased viscosity of the solid particle matrix together with the primary solid solution character should create a protracted release [7].

Ming-jun Tsai, Pao-chu Wu, Yaw-Bin Huang, Jia-You Fang *et al.* discussed on the improved stability and brain targeting of baicalein loaded in tocol nanostructured lipid carriers and concluded that gelucires and vitamin E may play a serious role in improving the pharmacokinetics and brain transport [8].

Monika Schafer Korting, Rainer Haag, Nadine B. Wolf *et al.* discussed on the opioids loaded sln and core multishell transporters could also be suitable for pain reduction and improved wound healing since both opioids and even unloaded carriers can improve keratinocyte migration and wound healing and major unwanted side effects aren't induced by the nanoparticulate carrier systems [9].

Robhash Kusam Subedi, Keon Wook Kang, Hoo Kyun Choi *et al.* discussed on the sln using doxorubicin as model drug prepared by solvent emulsification- diffusion method by using capmul and curdlan and therefore the cytotoxicity results revealed that lyophilized sln showed equal results even after one year at storage of refrigerated temperature [10].

Chih-Chieh chen, Tung Hu Tsai, Jia you Fang *et al.* discussed on the consequences of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers and therefore the refore the physicochemical characterization and the pharmacokinetics and concluded that the controlled release of drug was achieved by modifying the lipid matrix with various precirol and squalene ratios [11].

Sanjay Singh, Subhashis Chakraborty, Dali Shukla and Brahmeshwar Mishra *et al.* discussed on the role of lipids in bioavailability enhancement of poorly soluble drugs, mechanisms involved there in, approaches within the design of lipid based oral drug delivery systems with particular emphasis on solid dosage forms, understanding of morphological characteristics of lipids upon digestion *in vitro* lipid digestion models, *in vivo* studies and *in vitro–in vivo* correlation [12].

Malgorzata Sznitowska, Monika Gajewska, Aleksandra Radwanska *et al.* provided a quick background of bioavailability of diazepam from aqueous organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits which shows rapid and similar absorption because the solution during which elimination of the organic solvents from the answer makes it safer and more suitable as a paediatric drug [13].

Christopher J.H. Porter and William N. Charman *et al.* provided a quick background to the mechanism of access of medicine to the intestinal lymph and therefore the role of lipid digestion and absorption within the stimulation of lymphatic transport. The power of various lipid types to stimulate lymphatic drug transport is addressed, concentrating specifically on the impact of the category, chain length and degree of unsaturation of co-administered lipids [14].

Caitriona M.O. Driscoll *et al.* reviewed the present status of lymphatic transport of medicine using lipid based vehicle approach and analysed the success and limitations of a formulation approach using lipid based vehicles and highlights potential areas for further research [15].

Christopher J.H.Porter, Natalie L.Trevaskis and William N. Charman *et al.* detailed the mechanisms and capacity of lipids to reinforce drug solubilization within the intestinal milieu, recruit intestinal lymphatic drug transport (and thereby reduce first pass drug metabolism) and alter enterocyte based drug transport and disposition. Colin W. Pouton and Christopher [16].

J.H. Porter *et al.* discussed the properties of excipients and identified criteria for selection of excipients for lipid based formulations. They outlined the formulation strategies which will be used for every sort of lipid formulation and suggested a framework for the in vitro testing of every type and eventually addressed the selection of lipid formulations in reference to the physicochemical properties of the drug [17].

Peter Kaufmann, Johanna Mercke Odeberg, Karl-Gunnar Kroon and Peter Hoglund *et al.* developed a formulation containing fractionated oat oil consisting 50% neutral lipids and 50% polar lipids (mixed phospholipids and galactolipids) and medium chain monoglycerides in ratio 1:1, with a cyclosporine concentration of 10%, giving a formulation with similar absorption characteristics because the reference, Sandimmum Neoral and being approximately bioequivalent. Further, variety of things governing cyclosporine absorption were found the mixture of various lipid excipients, ratio between lipid excipients and degree of drug incorporation [18].

C.C. Muller-Goymann, M.A. Schubert *et al.* developed a formulation and characterization of surface modified solid lipid nanoparticles for absorptive protein loading by variation of both the lipid matrix and therefore the refore the emulsifier concentration within the continuous phase and the variation within the emulsifier concentration within the aqueous phase led to a degree dependent decrease in both particle size and zeta potential [19].

German A.B. Mahecha, Lucas A.M. Ferreira, Gisele A. Castro *et al.* discussed during this as formation of ion pairing as an alternate to enhance encapsulation and stability and to reduces skin irritation of retinoic acid loaded in solid lipid nanoparticles during which a cheap, simple and quick method which doesn't require the appliance of organic solvents, it became possible to get high loading capacity in solid lipid nanoparticles [20].

Na Zhang, Xuefeng Zhou, Qun Wang *et al.* is discussed as injectable actarit loaded solid lipid nanoparticles as passive targeting therapeutic agents for atrophic arthritis and therefore the above study concluded that actarit loaded solid lipid nanoparticles exhibited sustained release after an initial burst released and significantly improved the general targeting efficiency to the spleen of mice and these S.L.Ns. decreasing the danger of nephrotoxicity [21].

Yong Gan, Si-fei Han, Ting-ting Yao, Xin-xin Zhang, Li Gan, Chunliu Zhu *et al*. explored the use of lipid-based formulations to reinforce the oral bioavailability of the poorly water-soluble drug anethol trithione. Lipid composition influenced drug solubilization behavior, while formulation affected the lipid digestion rate finally influencing drug absorption [22].

Conclusion

Natural NMs have been present in the ecosystem for years, and they possess some mechanisms to cause less harmful effects among living organisms. However, research advancements have found some acute toxic effects of nanosized particles in living systems. From this review article, it can be noted that NMs from anthropogenic activities and engineered NMs in consumer products are able to cause toxic effects in living creatures. Additionally, emerging NPs, such as viral NPs and nanozymes, should be subjected to rigorous cytotoxicity tests to establish benign mechanisms of application and dosage levels. In order to minimize or avoid the potential hazards of engineered NMs in consumer products, regulations and laws have been implemented in many countries.

References

1. United Nations. Questions about Nanotechnology. 2012; https://www.epa.gov/chemical-research/research-nanomaterials (accessed Aug 21, 2014). Return to citation in text
2. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology. Federal Drug Administration: USA, 2011. https://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm (accessed Jan 25, 2016).
3. Future Trends in Microelectronics: The Nano Millennium (Eds: S. Luryi, J. Xu, A. Zaslavsky), Wiley-Interscience, New York, 2002.
4. Marc Muchow, Philippe Maincent, Rainer H. Müller Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery, Drug Development and Industrial Pharmacy. 2008; 34(12):1394-1405
5. Development and evaluation of isradipine via rutin-loaded coated solid-lipid nanoparticles.
6. Kumar V, Chaudhary H, Kamboj A Interv Med Appl Sci. 2018; 10(4):236-246.
7. Lv Q, Yu A, Xi Y *et al*. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009; 372(1-2):191–198.
8. Tsai MJ, Wu PC, Huang YB, Chang JS, Lin CL, Tsai YH *et al*. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. International journal of pharmaceutics. 2012; 423(2):461-470.
9. Haag R. Supramolecular drug- delivery systems based on polymeric core–shell architectures. Angewandte Chemie International Edition. 2004; 43(3):278-282.
10. Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. European journal of pharmaceutical sciences. 2009; 37(3-4):508-513.
11. Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. European Journal of Pharmaceutics and Biopharmaceutics. 2010; 74(3):474-482.
12. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid–an emerging platform for oral delivery of drugs with poor bioavailability. European Journal of Pharmaceutics and Biopharmaceutics. 2009; 73(1):1-15.
13. Sznitowska M, Gajewska M, Janicki S, Radwanska A, Lukowski G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. European journal of pharmaceutics and biopharmaceutics. 2001; 52(2):159-163.
14. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature reviews Drug discovery. 2007; 6(3):231-248.
15. Gooding M, Malhotra M, Evans JC, Darcy R, Driscoll, C.M., 2016. European Journal of Pharmaceutics and Biopharmaceutics Oligonucleotide conjugates–Candidates for gene silencing therapeutics, 2007.
16. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature reviews Drug discovery. 2007; 6(3):231-248.
17. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature reviews Drug discovery. 2007; 6(3):231-248.
18. Odeberg JM, Kaufmann P, Kroon KG, Höglund P. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. European journal of pharmaceutical sciences. 2003; 20(4-5):375-382.
19. Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. European journal of pharmaceutics and biopharmaceutics. 2005; 61(1-2):77-86.
20. Castro GA, Coelho ALL, Oliveira CA, Mahecha GA, Oréfice RL, Ferreira LA. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. International journal of pharmaceutics. 2009; 381(1):77-83.
21. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. International journal of pharmaceutics. 2008; 352(1-2):273-279.
22. Han SF, Yao TT, Zhang XX, Gan L, Zhu C, Yu HZ *et al*. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. International journal of pharmaceutics. 2009; 379(1):18-24.